Human Umbilical Cord Blood-derived Mononuclear Cell Transplantation Improves Pulmonary Arterial Hypertension in Immunodeficiency Mouse

背景和目标。本研究的目的是探讨人脐带血源性单核细胞（hub - mnc）移植是否能改善单核碱（MCT）治疗小鼠肺动脉高压（PAH）的发展。hub - mnc移植可能对几种具有原始肺血管的先天性心脏缺陷具有新的治疗潜力。方法。采用BALB/ c Slc-nu免疫缺陷小鼠建立mct诱导的PAH模型。HUCB-MNCs调整为1 × 107/ 0。浓度为25ml，在MCT给药4周后静脉注射。将小鼠分为五组：(1)车辆注射小鼠；(2) mct处理小鼠；(3) hub - mnc移植用于PAH小鼠；(4) hub - mnc +血浆移植治疗PAH小鼠；(5) PAH小鼠血浆移植。超声心动图通过右室间隔与左室重量之比（RV/ S+ LV）、肺动脉小动脉内侧厚度、肺动脉主动脉肺加速时间/射血时间（PAT/ ET）评估PAH。结果。有血浆或无血浆的hub - mnc移植分别显著改善了RV/ S+ LV比值、小肺动脉内侧厚度和PAT/ ET。结论。我们的数据显示，hub - mnc移植可改善mct诱导的PAH，其疗效取决于hub - mnc本身

Backgrounds and Objectives. The purpose of this study is to investigate whether human umbilical cord blood-derived mononuclear cell(hUCB-MNC) transplantation improves the development of pulmonary arterial hypertension(PAH) in monocrotaline(MCT)-treated mice. HUCB-MNC transplantation may have a new therapeutic potential for several congenital heart defects with primitive pulmonary vasculatures. Methods. MCT-induced PAH model was made using BALB/ c Slc-nu immunodeficiency mouse. HUCB-MNCs were adjusted to 1 x 107/ 0. 25 mL of concentration, and injected intravenously into those mice 4 weeks after MCT administration. The mice were divided into five groups :(1) vehicle-injected mice ;(2) MCT-treated mice ;(3) hUCB-MNC transplantation for PAH mice ;(4) hUCB-MNC+ plasma transplantation for PAH mice ;(5) plasma transplantation for PAH mice. Assessment of PAH were performed by the ratio of right ventricular to ventricular septum plus left ventricular weight(RV/ S+ LV), medial thickness of small pulmonary arteries, and pulmonary acceleration time/ ejection time(PAT/ ET) of the main pulmonary artery by echocardiography. Results. RV/ S+ LV ratio, medial thickness of small pulmonary arteries and PAT/ ET were significantly improved by hUCB-MNC transplantation with or without plasma, respectively. Conclusions. Our data shows that hUCB-MNC transplantation improves MCT-induced PAH and its efficacy is dependent on hUCB-MNCs themselves